reserpine · Sandoz · NDA 009627, 009663, 009667, 009838, 009859, 010441, 011185
Reserpine
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 16
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 009627 · 001 · discontinued | tablet, oral | 0.1MG | open |
| 009627 · 002 · discontinued | tablet, oral | 0.25MG | open |
| 009663 · 001 · discontinued | tablet, oral | 0.1MG | open |
| 009663 · 003 · discontinued | tablet, oral | 0.25MG | open |
| 009667 · 001 · discontinued | tablet, oral | 0.1MG | open |
| 009667 · 002 · discontinued | tablet, oral | 0.25MG | open |
| 009838 · 001 · RLD · discontinued | tablet, oral | 0.1MG | open |
| 009838 · 002 · RLD · discontinued | tablet, oral | 0.25MG | open |
| 009859 · 001 · discontinued | tablet, oral | 0.1MG | open |
| 009859 · 002 · discontinued | tablet, oral | 0.25MG | open |
| 010441 · 001 · discontinued | tablet, oral | 0.1MG | open |
| 010441 · 002 · discontinued | tablet, oral | 0.25MG | open |
| 010441 · 003 · discontinued | tablet, oral | 0.5MG | open |
| 010441 · 004 · discontinued | tablet, oral | 1MG | open |
| 011185 · 001 · discontinued | tablet, oral | 0.1MG | open |
| 011185 · 002 · discontinued | tablet, oral | 0.25MG | open |